Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Pfizer As Cornerstone Investor, Will Shanghai Pharmaceutical Be Largest Pharma IPO Ever?

This article was originally published in The Pink Sheet Daily

Executive Summary

The company has secured four cornerstone investors to purchase shares together worth $550 million, with total net proceeds from the global offering possibly reaching as high $2.46 billion.

You may also be interested in...



China Distributor Consolidation Heats Up: Sinopharm Looks To Raise $440 Million Ahead Of Shanghai Pharma IPO

SHANGHAI - China's largest drug distributor Sinopharm Group Co. Ltd. April 25 placed a secondary offering of roughly 138 million H shares in Hong Kong looking to raise HK$3.4 billion ($440 million) to fund more acquisitions. The move comes just ahead of the initial public offering in Hong Kong of Sinopharm's biggest competitor Shanghai Pharmaceutical Holdings Co. Ltd, and will add more heat to the consolidation war in China's distribution sector

Pfizer Looks To Team Up With Shanghai Pharmaceutical To Co-develop And Commercialize Pfizer Products In China

SHANGHAI - The world's largest pharmaceutical company Pfizer Inc. and China's second-largest distributor Shanghai Pharmaceutical Holdings Co. Ltd announced April 21 a memorandum of understanding to explore business opportunities, including the potential to jointly register, commercialize and distribute in China an innovative compound from Pfizer

Reading Into Pfizer's Changes: First Steps For New CEO

Pfizer Inc.'s new CEO Ian Read came out of the gates strong during the company's year-end financial presentation Feb. 1, with news that investors greeted warmly: additional, unexpected cuts to R&D and further R&D reorganization, a $5 billion share buyback program, and assurance that all options are on the table when it comes to Pfizer's diversified portfolio of businesses.

Related Content

Topics

UsernamePublicRestriction

Register

PS072226

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel